The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose–response meta-analysis
- 140 Downloads
Background and aims
Liver stiffness measurement (LSM) by transient elastography (TE) has been assessed for the evaluation of clinically relevant outcomes in patients with chronic liver diseases (CLDs) while with variable results. This systematic review and meta–analysis aims to investigate the relationship between baseline LSM by TE and the development of clinically relevant outcomes.
The systematic review identified eligible cohorts reporting the association between baseline LSM by TE and risk of hepatic carcinoma (HCC), hepatic decompensation (HD), all–cause and/or liver–related mortality and liver–related events (LREs) in CLD patients. Summary relative risks (RRs) with 95% confidence intervals (CIs) were estimated using a random–effect model. The dose–response association was evaluated by generalized least squares trend (Glst) estimation and restricted cubic splines. Commands of GLST, MKSPLINE, MVMETA were applied for statistical analysis.
62 cohort studies were finally included, reporting on 43,817 participants. For one kPa (kilopascal) increment in baseline liver stiffness (LS), the pooled RR (95% CI) was 1.08 (1.05–1.11) for HCC, 1.08 (1.06–1.11) for all–cause mortality, 1.11 (1.05–1.17) for liver-related mortality, 1.08 (1.06–1.10) for HD and 1.07 (1.04–1.09) for LREs. Furthermore, the nonlinear dose–response analysis indicated that the significant increase in the risk of corresponding clinically relevant outcomes turned to a stable increase or a slight decrease with increasing baseline LS changing primarily in the magnitude of effect rather than the direction.
The dose–response meta-analysis presents a combination between the levels of baseline LS and RRs for each clinically relevant outcome. TE, which is noninvasive, might be a novel strategy for risk stratification and identification of patients at high risk of developing these outcomes.
KeywordsFibroscan Liver Cancer Cirrhosis Outcome
Chronic hepatitis B
Chronic liver disease
Generalized least-squares trend
Hepatitis B virus
Hepatitis C virus
Human immunodeficiency virus
Liver stiffness measurement
Upper limit of normal
The study was supported by the National Nature Science Foundation, No. 81670541; and National Science and Technology Major Project of China, No. 2013ZX10002004 and No. 2017ZX10203202.
Compliance with ethical standards
Conflict of interest
Yue Shen, Sheng-Di Wu, Ling Wu, Si-Qi Wang, Yao Chen, Li–Li Liu, Jing Li, Chang-Qing Yang, Ji-Yao Wang, Wei Jiang declare that they have no conflict of interest.
- 9.Calvaruso V, Bronte F, Simone F, et al. Liver stiffness at baseline predicts decompensation and hepatocellular carcinoma in patients with compensated HCV cirrhosis. Hepatology. 2012;56:930A–1A.Google Scholar
- 10.Vicente FJ, Barreiro P, Vispo E, et al. Baseline liver stiffness and achievement of sustained virological response predict liver complications and death in HIV/HCV coinfected patients receiving peginterferon/ribavirin therapy. Hepatology. 2012;56:650A–1A.Google Scholar
- 14.Higgins JPT, Green S (eds) Cochrane Handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org. Accessed 16 May 2013.
- 24.Song ZZ. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008;48(349–350):350.Google Scholar
- 27.Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21:77–82.Google Scholar